

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT RESIGNATION OF THE CHAIRMAN OF THE COMPANY

This announcement is made by Sinopharm Group Co. Ltd. (the “**Company**”) pursuant to Rules 13.09 (2) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company announces that on 12 January 2021, the Company received the resignation from Mr. Li Zhiming, the chairman of the Board. Due to personal reasons, Mr. Li Zhiming (“**Mr. Li**”) tendered his resignation as the chairman of the Board, an executive director, the chairman of the nomination committee of the Board, the chairman of the strategy and investment committee of the Board and a member of the legal compliance committee of the Board with immediate effect. Mr. Li has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders and creditors of the Company.

At present, the existing directors and management of the Company are performing their duties as usual, and the Company continues to conduct its operations as usual.

The Board has elected Mr. Yu Qingming to act as chairman of the Board on 12 January 2021 in accordance with the articles of association of the Company (“**Articles of Association**”). Mr. Yu Qingming will perform his duties in accordance with the Company Law, Articles of Association and the relevant bylaws of the Company. The Board will continue to operate in accordance with the applicable laws and regulations to ensure the stability of the Company's operations.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinopharm Group Co. Ltd.
Wu Yijian
Joint Company Secretary

Shanghai, the PRC
12 January 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*